Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 39,395 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

39,395 Papers indexed
1,440 Papers AI scored
39,395 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

39395 results
B
AI -
Standard 76.22
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 76.1; sample size: 90.0; recency: 100.0; abstract quality: 85.0.

B
Decision-making when a child with haematological malignancy relapses following haematopoietic stem cell transplantation: A meta-ethnographic review.
PMID 41045322 Published: 2025-10-04 Ingested: 2026-08-02 12:05 AM Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
AI -
Standard 76.22
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 36.1; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 76.22
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 46.1; sample size: 90.0; recency: 90.0; abstract quality: 100.0.

B
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab.
PMID 40059970 Published: 2024-12-05 Ingested: 2026-08-02 12:03 AM JHEP reports : innovation in hepatology
AI -
Standard 76.22
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 51.1; sample size: 80.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Standard 76.22
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 46.1; sample size: 20.0; recency: 80.0; abstract quality: 100.0.

B
Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.
PMID 42377093 Published: 2026-06-30 Ingested: 2026-08-02 12:07 AM Clinical cancer research : an official journal of the American Association for Cancer Research
AI -
Standard 76.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 36.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.2/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 33.5; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Prolonged Grief-Related Symptoms Among Young Individuals After Loss of a Parent or Sibling to Cancer: A Systematic Review and Meta-Analysis.
PMID 41682741 Published: 2026-01-29 Ingested: 2026-08-02 12:06 AM Journal of clinical medicine
AI -
Standard 76.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.2/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 26.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Hepatitis B vaccination coverage rates among under-five children in India: a systematic review and meta-analysis protocol.
PMID 40980135 Published: 2025-09-04 Ingested: 2026-08-02 12:03 AM Frontiers in pediatrics
AI -
Standard 76.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.2/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 26.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Clustering of childhood acute leukemia in Finland: a nationwide register-based study.
PMID 40272762 Published: 2025-04-24 Ingested: 2026-08-02 12:04 AM Cancer causes & control : CCC
AI -
Standard 76.2
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.2/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 16.0; sample size: 90.0; recency: 90.0; abstract quality: 100.0.

Previous
Page 340 of 3283
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic